Fuss Brands Corp.
DelistedCIK 926844fmd_0QEW3Y371AT3Y012QGPWVMNRHTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Nov 01, 2009 to Jul 31, 2025, 31 periods
| Line item | FY2010 | FY2011 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | – | – | – | – |
| Cost of revenue | 26 | 30 | – | – | – | – | – |
| Gross profit | 29 | 43 | – | – | – | – | – |
| Research and development | 3 | 4 | – | – | – | – | – |
| Selling, general and administrative | 9 | 10 | – | – | – | – | – |
| Total operating expenses | 12 | 14 | 0 | 0 | 0 | 1 | 3 |
| Operating income | 18 | 30 | 0 | (0) | (0) | (1) | (3) |
| Interest expense | – | – | – | – | – | 0 | 0 |
| Interest and investment income | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | – | – | 0 | – | – | – | – |
| Income before taxes | 18 | 30 | 0 | (0) | (0) | (1) | (3) |
| Income tax expense | 0 | 4 | 0 | – | – | – | – |
| Net income from continuing operations | 18 | 26 | 0 | – | – | – | – |
| Net income | 18 | 26 | 0 | (0) | (0) | (1) | (3) |
| Net income to common shareholders | – | – | – | 0 | 0 | 1 | – |